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InﬂammationUpon activation, platelets secretemore than 300 active substances from their intracellular granules. Platelet dense
granule components, such as ADP and polyphosphates, contribute to haemostasis and coagulation, but also play a
role in cancer metastasis. α-Granules contain multiple cytokines, mitogens, pro- and anti-inﬂammatory factors
and other bioactive molecules that are essential regulators in the complex microenvironment of the growing
thrombus but also contribute to a number of disease processes. Our understanding of the molecular mechanisms
of secretion and the genetic regulation of granule biogenesis still remains incomplete. In this reviewwe summarise
our current understanding of the roles of platelet secretion in health and disease, and discuss some of the hypoth-
eses that may explain how platelets may control the release of its many secreted components in a context-speciﬁc
manner, to allow platelets to play multiple roles in health and disease.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Platelets have been known to contribute to thrombosis and
haemostasis since their ﬁrst identiﬁcation by Bizzozero in the 1880s
[1]. Recent evidence suggests that their functions extend beyond
the immediate environment of the thrombus and platelets have been
implicated in a number of other physiological responses aimed at
safeguarding the integrity of the vessel. On the other hand, their prop-
erties as haemostatic and inﬂammatory cells can result in disease states
under certain conditions. Platelets can ‘communicate’ with each other
and with other cells via a range of bioactive substances secreted from
their intracellular granules. In this review, the contribution of platelet
secretion to those processes will be discussed.2. Platelet activation cascade
Under physiological conditions, platelets circulate in close proximity
to the vascular walls [2], but are protected from untimely activation by
the healthy endothelial monolayer which provides a natural ‘barrier’ to
thrombosis, as well as by the release of inhibitory mediators such as
nitric oxide and PGI2 from the intact endothelium. Platelets become
activated when the continuity of the endothelial layer is disrupted and
the underlying subendothelial matrix is exposed, or if inﬂammation
perturbs the endothelium. Platelet receptors then interactwith collagen
and von Willebrand Factor among others, which capture the plateletsarmacology, Medical Sciences
4 117 331 1435; fax: +44 117
. This is an open access article underand induce activation signals. The initial events following platelet
activation are summarised in Fig. 1.
After the initial ‘platelet plug’ is formed at the site of injury, engage-
ment of the coagulation cascade leads to ﬁbrin mesh formation that en-
capsulates and strengthens the thrombus. As well as serving as adhesion
sites for coagulation factors (via surface exposure of phosphatidylserine,
PS), platelets themselves are an important source of those factors (for
example Factors V [3] andXIII [4,5]), and other components that regulate
coagulation such as polyphosphates [6,7] and prothrombin [8].
Platelets can also become activated via G-protein coupled receptor
(GPCR) signalling downstream from soluble agonists forming at the site
of thrombus. Those soluble agonists, and in particular ADP released from
dense granules of activated platelets, precipitate a number of positive feed-
back cascades leading to rapid activation of large numbers of platelets. Ulti-
mately, an orchestrated ‘effort’ of many other secreted mediators and cells
results in restoration of vessel integrity. Arguably, secretion is the most far
reaching result of platelet activation, and as such can also account for func-
tions of platelets beyond the immediate environment of the thrombus.
Therefore platelet secretion is at the heart of the control of vascular integri-
ty, in health and disease, and is the focus of this review.3. Secretion in primary haemostasis
3.1. Dense granules
Dense granules contain a range of small molecules [9] such as ADP,
ATP, GDP, 5-HT, pyrophosphate, magnesium and calcium. Historically
release from dense granules was described as ‘fast’ and indeed a recent
study by Jonnalagadda et al. [10] showed that the release of [3H]-
serotonin occurred more rapidly than PF-4 from α-granules or β-the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Fig. 1. Schematic of platelet activation cascade leading to the haemostatic plug formation. Platelet adhesion to ECM components via integrin or GPVI receptors or activation with soluble
agonists via GPCR receptors leads to platelet activation. One of the hallmarks of platelet activation is secretion of bioactive molecules from dense and α-granules, which can then act to
activate further platelets, as well as in an autocrine manner to drive positive feedback cascade. ‘Inside-out’ signalling initiated by platelet activation also causes activation of integrin
αIIbβ3. Platelets also undergo a dramatic shape change, increasing their surface area available for adhesion to ECM and to one another. Activated integrin αIIbβ3 and ﬁbrin contribute
to formation of the initial aggregate or platelet plug. Platelets also expose PS providing attachment sites for coagulation factors. The coagulation cascade contributes to the stabilisation
of the thrombus.
154 E.M. Golebiewska, A.W. Poole / Blood Reviews 29 (2015) 153–162hexosaminidase from lysosomes, regardless of the agonist used to
stimulate platelets [10].
Smallmolecules released fromdense granules togetherwith synthe-
sised thromboxane A2 act back on circulating platelets and contribute to
the positive feedback signalling that sustains platelet aggregation. The
central role of the ADP–P2Y12 receptor axis in haemostasis is particular-
ly well established. Platelet adhesion on vWF, inside-out activation of
integrin αIIbβ3 and P-selectin expression are all defective in P2Y12−/−
mice [11]. Recently, chemically mutagenised mice lacking Munc13-4
(Unc13DJinxmice) that show a complete absence of platelet dense gran-
ule secretion were generated. Those animals were also found to have
signiﬁcantly reduced aggregation and other markers of platelet
activation such as α-granule and lysosome secretion and integrin acti-
vation [12], conﬁrming that it is the secreted ADP rather than plasma
ADP that contributes to those processes. They also failed to form throm-
bi in the in vivo and in vitro models of thrombosis [13]. Co-stimulation
with exogenous ADP could partially rescue platelet function, underlining
the essential role of ADP in driving the positive feedback loop and thus the
platelet primary haemostatic response [13]. Interestingly, Munc13-4 dele-
tion did not affect intracranial bleeding following stroke induction in
mice, while at the same time they were protected from stroke progression
[14]. This apparent paradox hints at different roles for ADP/P2Y12 signalling
in haemostasis and thrombosis, possibly even in different disease scenarios.
The role of ADP emerges as more important and complex than initially
thought and may account for some distinguishing features of thrombosis
versus haemostasis. ADP/P2Y12 mediated signalling also enhances signal-
ling towards procoagulant activity and thrombin activation [15].3.1.1. ADP and the ‘core and shell’ model of thrombus structure
Despite many different agonists shown to drive platelet activation
in vitro to completion, it is now known that in vivo platelet activation
is non-homogeneous, possibly attributable to variations in shear
under physiological conditions [16,17]. α-Granule secretion and calci-
um mobilization have also been shown to be heterogeneous [18].
In a recent study, Stalker et al. suggested a new model of thrombus
structure, taking into account that non-uniform activation pattern.
They showed that two distinct populations of platelets are present in agrowing thrombus in vivo: a ‘core’ of more stable P-selectin expressing
platelets, andamoreporous ‘shell’, containing less activated, P-selectinneg-
ative platelets [19]. While the ‘core’ seemed to be more dependent upon
thrombin and local contact-dependent activation, the recruitment of plate-
lets to the ‘shell’was shown to be critically dependent uponADP signalling,
with P2Y12 inhibition signiﬁcantly decreasing the size of the ‘shell’ and not
affecting the ‘core’. They also show that permeability of the ‘core’ to plasma-
borne molecules is limited, suggesting that efﬂux of platelet granule con-
tents in that tightly packed region could be similarly limited [19,20].
The most effective anti-thrombotic treatments currently used
speciﬁcally target the ADP/P2Y12 positive feedback cascade, blocking
the P2Y12 receptors and thus limiting platelet activation and aggregation
and the risks of pathological thrombosis, particularly in the management
of coronary heart disease [21]. However, the central role of the ADP/P2Y12
axis in haemostasis means that abnormal bleeding often occurs in pa-
tients treated with potent P2Y12 inhibitors such as clopidogrel, prasugrel
or ticagrelor [22]. On the other hand, the new core and shell model
could account for the ability of the same agents to reduce platelet accu-
mulation without always causing bleeding, as they would not affect the
initial platelet adhesion or the size of the ‘core’ [19]. It is possible that in
humans, interindividual variations in platelet activity account for those
differences. Increasing our understanding of ADP/P2Y12 signalling may
help in discoveringmore selective platelet inhibitors that could speciﬁcal-
ly limit thrombosis without causing bleeding.3.1.2. Polyphosphate in coagulation
Dense granule secretion is also important in coagulation. Released
calcium for instance is required at several steps of the coagulation
cascade and for activation of the prothrombinase pathway. Recently
more insight was gained into the role of another dense granule cargo
molecule, polyphosphate (polyP). PolyP is a highly anionic linear poly-
mer that is synthesised from ATP and secreted by platelets after activa-
tion [23]. Synthetic polyP could restore defective clot formation in
platelet-rich plasma from Hermansky–Pudlak patients who lack dense
granules [24], suggesting a role in haemostasis. The putativemechanism
involves direct polyP binding to Factor XII, thus triggering coagulation
by the tissue factor-independent, contact activation pathway [24,25].
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to have no bleeding tendencies suggesting that the contact pathway is
not essential in primary haemostasis, contrary to the tissue factor
pathway [26]. This would not support the idea of the polyP–Factor XII
pathway being essential for haemostasis. However, more recent studies
of mice deﬁcient in hexakisphosphate 6 (IP6) kinase required for
synthesis of polyP showed that a 3-fold reduction in polyP levels led
to widespread platelet function and coagulation defects, again suggest-
ing a role in haemostasis [6]. As well as its debatable role in Factor XII
activation, polyP was also found to accelerate thrombin generation
[27] and enhance ﬁbrin clot stability [28]. Although the role of polyP
and its potential in antithrombotic therapy remain largely unclear, the
general consensus is that this previously under-appreciated inorganic
molecule may represent an important player in the thrombotic–
haemostatic environment [7]. Indeed, in 2012 two groups showed that
pharmacological inhibition of polyP could prevent thrombosis without
increasing surgical bleeding inmousemodels [29,30], again emphasising
the multifaceted role of the platelet secretome in haemostasis.
3.2. α-Granules
A number of α-granule cargoes, such as vWF and ﬁbrinogen, act to
propagate activation and aggregation of platelets at the site of injury.
In addition, an estimated one third to a half of total αIIbβ3 and one
third or more GPVI receptors reside in α-granules and are trafﬁcked to
the surface of the platelet following platelet activation, further amplify-
ing platelet aggregation [31].
3.2.1. Thrombospondin and CD36 in thrombus stabilisation
In addition, a recent study identiﬁed the thrombospondin (TSP1)/
CD36 axis as another pathway that may help differentiate physiological
haemostasis from thrombosis. TSP1 is one of the most highly expressed
proteins in platelet α-granules and unlike vWF or ﬁbrinogen is present
in plasma in very low concentrations. As shown by Kuijpers et al.,
knockdown of the TSP1/CD36 axis in mouse platelets leads to a defect
in thrombus stabilisation without affecting primary haemostasis [32].
Initial platelet adhesion under shear in whole blood was not affected
in Tsp1−/−mice, but activation as measured by PS exposure was signif-
icantly reduced. Similarly, they also showed that in the whole blood
perfusion model, Tsp1−/− or CD36−/− thrombi disintegrated faster,
but the thrombus size was the same between genotypes. In vivo both
CD36−/− and Tsp1−/− mice showed longer time to occlusion and
increased embolization in thrombosis assays. The Tsp1/CD36 axis may
therefore be another contributor to the complex haemostasis/thrombosis
balance.
3.2.2. α-Granules in coagulation
Factors V, XI and XIII are all stored in α-granules, as is the throm-
bin precursor, prothrombin. Platelet derived Factor V is a potent
procoagulant, thanks to higher resistance to activated Protein C-
mediated inactivation than its plasma counterpart and targeted release
at the site of injury [33,34]. It was also shown to explain the paradoxi-
cally mild bleeding diathesis in patients with congenital plasma Factor
V deﬁciency, its residual secretion from platelets being able to rescue
thrombin generation and thereby prevent bleeding [3]. Likewise,
releasate from washed platelets, even from plasma Factor XI-deﬁcient
donors, was able to correct the clotting defects observed in Factor
XI-deﬁcient plasma in vitro [35].
Importantly, platelet α granules also contain numerous anti-
coagulation cargoes. Tissue factor pathway inhibitor (TFPI), protein S,
protease nexin-2 (amyloid β-A4 protein), plasmin and its inactive pre-
cursor plasminogen can all limit progression of coagulation by inhibiting
or cleaving activated clotting factors or initiating ﬁbrinolysis [31]. These
apparently conﬂicting functions of platelets in the coagulation pathway
are essential to sustain haemostatic balance and to prevent pathological
thrombosis under physiological conditions.4. Importance of secretion in normal haemostasis: lessons from
patients
Since the primary function of platelets is haemostasis, or prevention
of bleeding, it is no surprise that many patients presenting with abnor-
mal bleeding are found to have defects in their platelet function and se-
cretion. There are two classes of heritable bleeding disorders associated
with poor platelet secretion: (i) those that result from defective platelet
granule formation, leading to low numbers of platelet granules and
cargo and (ii) those that arise from defects in secretory machinery,
where plateletsmay have normal numbers of granules, but have defects
in their ability to secrete them. Both of these classes of secretion
deﬁciency have helped us to understand the role and mechanisms of
platelet secretion on different levels.
4.1. Platelet granule formation defects
Platelets derive from megakaryocytes (MKs) — large polyploid pro-
genitor cells that reside primarily in the bone marrow. The synthesis
and packaging of granules are thought to occur mainly at the early
megakaryocyte stage [36], but little is known about exact mechanisms
of granule sorting and trafﬁcking to their ﬁnal destination in platelets
[37]. Limited evidence suggests that, unlike most of the other secretory
organelles that bud from the Golgi apparatus, both α- and dense gran-
ules may instead originate from the multivesicular bodies (MVBs)/late
endosomes in megakaryocytes [38]. Most inherited platelet storage
defects involve either α- or dense granules, but not both, suggesting the
existence of distinct granule biogenesis pathways for the two subtypes.
Understanding of congenital platelet disorders has mademajor contribu-
tions to our understanding of granule biogenesis as well as shed light on
the roles of platelet granules in haemostasis and thrombosis.
4.1.1. Dense granules
Since dense granules are lysosome-related organelles, the best de-
scribed dense granule formation defects are associated with systemic
lysosome-like organelle biogenesis defects [39]. Therefore patients
tend to manifest with other systemic lysosome-related organelles
symptoms such as innate immunity defects [40], and in both humans
and related mice genetic models of disease melanosome deﬁciency,
resulting in defective eye, skin and hair or coat pigmentation, is often
present [41].
Hermansky–Pudlak Syndrome (HPS) was ﬁrst described in 1976
[42], but it is only recently that advances in genomic approaches
allowed for identiﬁcation of the genes responsible for this disease
which in turn increased our understanding of granule biogenesis in
platelets. The lack of a secondary aggregation response of platelets to
exogenous stimuli in HPS patients means that bleeding complications
are common, although bleeding is not the most common cause of
death among HPS patients. Bleeding manifestations include spontane-
ous bruising, epistaxis,menorrhagia, and prolonged oozing after trauma
or minor surgery such as a tooth extraction [43]. Distinct subtypes of
HPS are caused by defects in one of at least eight genes (HPS-1 through
HPS-8) encoding the HPS proteins which interact with each other in
complexes termed BLOCS 1–3 (biogenesis of lysosome-related organ-
elles complexes 1–3) [44].
Another dense granule storage defect with much poorer prognosis
than HPS is Chediak–Higashi syndrome (CHS) [45]. Again, patients
lack dense granules and present with bleeding diathesis and decreased
pigmentation, accompanied with severe immunologic defects and neu-
rological dysfunction [46]. The CHS gene has been cloned and a series of
mutations described, but the function of the affected protein (lysosomal
trafﬁcking regulator, LYST) remains unknown [46]. Its distinct structural
domains including the BEACH (Beige and Chediak–Higashi) domain
[47] suggest a function in membrane trafﬁcking and organelle biogene-
sis, similar to genes affected in HPS.
Fig. 2. Currently accepted model of platelet secretion. Three SNARE proteins: trans-
membrane VAMP8, with some additional VAMP2 and VAMP3 contribution (blue),
and membrane-anchored STX11 (green) and SNAP23 (red) form the core SNARE
complex in platelet secretion. MUNC13-4 and MUNC18-2 (purple) are also essential
for secretion, although their exact mechanism of action is not fully understood.
RAB27b, along with other small GTPases (orange) is also implicated.
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defects in lysosomal-related organelles are quite common and can re-
sult inmild to severe secretion defectswith orwithout affecting second-
ary aggregation, and thus presenting with varying degrees of bleeding
diathesis [48]. Identiﬁcation of the genes involved in those defects
could potentially help understand the differences between haemostasis
and thrombosis for clinical beneﬁt (see later sections in this review).
4.1.2. α-Granules
α-Granules are the storage site for many proteins including those
synthesised inMK or endocytosed fromplasma,withmultiple functions
in haemostasis and other processes described later in this article.
Mechanisms of α-granule formation are less well understood. Defects
of protein packaging and α-granule biogenesis in MK result in a set of
heterogeneous disorders collectively known as Grey Platelet Syndrome,
resulting in a usually mild to moderate bleeding disorder which can
however on occasions be life-threatening [49]. In 2011, next generation
DNA and RNA sequencing technologies were used by 3 groups indepen-
dently to identify mutations in the NBEAL2 (neurobeachin-like 2) gene
in a large number of GPS cases [50–52]. NBEAL2 belongs to the same
gene family as LYST responsible for CHS, and appears to be directly im-
plicated in α-granule biogenesis in MKs. Nbeal2−/−mice show defects
in primary thrombus formation and are protected from inﬂammatory
brain infarction following focal cerebral ischaemia [53,54]. They also
have defects in tissue repair after injury, reﬂecting the importance of
platelet α-granule secretome beyond the haemostasis/thrombosis con-
text [53]. Another α-granule biogenesis disorder, arthrogryposis, renal
dysfunction, cholestasis syndrome (ARC) is a severe multisystem child-
hood disorder caused by mutations in a novel Sec1/Munc18 family
member VPS33B [55]. VPS33B is known to be involved in intracellular
trafﬁcking in yeast, but its role in α-granule biogenesis remains to be
elucidated. Quebec syndrome on the other hand is not associated with
granule biogenesis defects as such, but with degradation of α-granule
cargoes due to marked increase in urokinase plasminogen activator at
the megakaryopoietic stage, resulting in production of proﬁbrinolytic
platelets [56,57].More research is needed to fully understand the genetic
basis forα-granule formation and defectswhich could perhaps enable us
tomodify them for clinical beneﬁts associatedwith their multifunctional
cargoes.
4.2. Defects in secretory machinery
Relatively recently another family of congenital disorderswas linked
with its genetic correlates to help us understand how secretion in plate-
lets is regulated. Familial haemophagocytic lymphohistiocytosis (FHL)
patients present with an abnormal bleeding diathesis without anymor-
phological changes to platelet granules. Unlike storage pool disorders
that rarely affect both α- and dense granules, some FHL subtypes affect
all granule types, suggesting a common ‘core’ mechanism to regulate
secretion. In addition, systemic complications beyond platelets suggest
a common mechanism of secretion in other haematopoietic cells.
Indeed, platelets share their secretory machinery, centred on the
Soluble NSF Attachment Protein Receptor (SNARE) family of proteins,
with other mammalian cells. In the simplest model, the universal
SNARE-mediated fusion involves transport of the vesicle to the target
membrane and ‘priming’ it for release, followed by calcium-mediated
conformational change in the SNARE complex that leads to the comple-
tion of membrane fusion, and eventually to the release of granule
contents [58]. Four core SNARE proteins, characterised by 60 amino
acid coiled-coil SNARE domains, as well as SNARE-associated proteins
such as Sec1/Munc18, Munc13-4 and small GTPase families regulate
that process [59], but our understanding of the machinery remains
incomplete. SNAREs were ﬁrst identiﬁed in platelets in 1997 [60], and
since then, our understanding of the mechanisms of secretion has in-
creased tremendously (see Fig. 2). However, some questions regarding
the identity of the central ‘players’ still remain to be addressed.In FHL subtypes 3, 4 and 5, deﬁciency ofMUNC13-4 [61], syntaxin 11
(STX11) [62] and MUNC18-2 [63,64], respectively, leads to substantial
defects in platelet granule secretion. Prior to the discovery of those
genes, the mechanisms of SNAREs in human platelets were based
upon treatment of streptolysin-O permeabilised plateletswith function-
al blocking antibodies and the correlative evidence of phosphorylation
of certain proteins occurring at a similar rate to secretion [65–68].
Gene knockout mouse models of a range of SNAREs (namely vesicle-
associated membrane proteins, VAMPs) have also helped to identify
the potentially important players [69]. However, only studies on the
FHL patients provided unequivocal evidence supporting the role of
those three proteins in human platelets. Even the loss of the core
SNARE STX11 in FHL4 patients [62] or the knockout of VAMP8 coupled
with tetanus neurotoxin (TnT-LC) treatment in mouse platelets [69],
does not lead to full ablation of secretion, suggesting ranked redundan-
cy and compensation mechanisms [69]. As discussed in more detail in
our recent review (Golebiewska and Poole [59]), it is likely therefore
that additional SNAREs are involved in the regulation of secretion.5. Platelets — not only primary haemostasis
The roles of platelets are not limited to initial aggregation and plug
formation. The cascade of events leading to vessel repair is summarised
in Fig. 3. Platelets are known to be involved at all the stages of this
cascade, including coagulation, immune cell recruitment and inﬂamma-
tion, andwoundhealing, angiogenesis and remodelling. The importance
of platelets in each of the steps varies in different vasculatures. In
addition, our understanding of the mechanisms of thrombus formation
and haemostasis comesmainly from animal models where haemostasis
is initiated by physical injury to the healthy vessel. In humans, the
mechanism by which ECM becomes exposed to blood ﬂow, especially
in the arterial circulation, is more often than not rupture of an athero-
sclerotic plaque,which alsomeans the vesselmay be inﬂamed, stenosed
and generally unhealthy, adding to the complexity of those interactions.
Therefore themechanismsdiscussed here are likely to be anoversimpli-
ﬁcation of the pathological arterial thrombosis. Different mechanisms
are likely to contribute to venous and microvascular versus arterial
thrombosis, with alterations in sheer differentially inﬂuencing throm-
bus formation.
Fig. 3. Simpliﬁed illustration of events leading to vessel injury repair. Following the initial platelet plug formation, coagulation cascade activation results in production of ﬁbrin that
reinforces the thrombus. Then leukocyte recruitment from the blood leads to an inﬂammatory response and antimicrobial response. Finally, wound healing and vessel wall remodelling
lead to restoration of the continuity of the endothelium. Secretion of the 300+ bioactive substances from platelet intracellular stores is likely to be a major driver of these events.
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After the stable ﬁbrin and platelet rich clot forms to stop the imme-
diate bleeding, the further steps of the repair process begin. Close bidi-
rectional cooperation between the haemostatic and immune systems
is required to ensure restoration of normal tissue function following
the injury.
In the arterial circulation, the high shear environment leads to wash
out of any chemoattractant molecules from the site of the injury. There-
fore platelets stably adherent to the ECM are required for ‘capturing’
circulating immune cells and recruiting them to the thrombus. Platelet
α-granules mediate inﬂammatory responses both by expressing adhe-
sion receptors that facilitate interactions with endothelial cells and
leukocytes, and by secreting a wide range of chemokines. P-selectin
translocates to the cell surface from α-granules on adherent platelets
and can recruit circulatorymonocytes, neutrophils and lymphocytes, in-
ducing inﬂammatory responses in those cells [70]. Platelets also contain
abundant chemo- and cytokines, in particular CXCL4 (PF-4) and 7 at
concentrations 1000-fold greater than the plasma concentration [71].
PF-4 has been shown to drive monocyte activation and differentiation
[72], as well as neutrophil adhesion [73] and monocyte recruitment to
the endothelium [74].
Inﬂammatory cell inﬁltration of the arterial subendothelium, pro-
moted by platelet cytokines, also contributes to atherosclerotic plaque
formation [75]. In addition, serotonin released from dense granules
upon activation by the inﬂamed endothelium further contributes to
recruitment of immune cells to the vascular wall [76]. Transendothelial
migration of neutrophils both in human and mouse models of inﬂam-
mation, is at least in part mediated by a platelet α-granule-derived
P-selectin and P-selectin glycoprotein ligand (PSGL)-1 interaction [77].
In addition, the mechanism by which platelets are able to guide leuko-
cyte migration through thrombi has also recently been identiﬁed [78].
Release of NAP-2, the CXCR1/2 ligand, from platelet α-granules, leads
to a chemotactic gradient inside the growing thrombus. This in turn
enables leukocytes to migrate through the physical barrier which isthe growing thrombus and towards the site of the injury and endothe-
lium [78].
In addition to their essential roles in physiological responses to inju-
ry, platelet–immune cell interactions are also likely to be very important
in the pathophysiology of atherosclerotic plaque formation. Modulation
of platelet secretion could therefore help reduce plaque growth. For
example, inhibition of platelet derived CXCR4–CCL5 heterodimer
formation was shown to attenuate monocyte recruitment to inﬂamed
vessel wall in ApoE−/−mice [79] and also reduce aneurysm formation
in those animals.
5.2. Antimicrobial responses
Trauma to tissue or introduction of foreign objects into the vessel is
the most direct way by which bacterial and viral pathogens can invade
the body. Therefore it stands to reason that antimicrobial and
haemostatic responses are intimately linked. Platelets are the most nu-
merous cells ﬁrst to arrive at the site of injury, and the role of platelets in
combating pathogens is increasingly apparent. It has been known for
many years that platelets localize and adhere to sites of bacterial lesions
in the circulation, for example in endocarditis [80]. However, only in
2002 was it shown that many of the cytokines secreted by platelets
have direct microbicidal properties [81], and that platelets can directly
internalize pathogens [82]. At the same time, activation by pathogen-
associated molecular patterns (via Toll-like receptors, TLRs) leads to
the release of more cytokines, such as PF-4 or CCL5 (RANTES) which
leads to recruitment of circulating inﬂammatory cells [83] and ensures
a rapid response to infection. Interestingly, TLR-mediated platelet
responses to different bacterial species vary — for example, secretory
patterns of PDGF (platelet-derived growth factor) and RANTES,
but not P-selectin or PF-4 differs between platelets in response to
Escherichia coli or Salmonella species [84]. The increasing importance
of platelets in the antimicrobial response has been reviewed exhaustive-
ly by Yeaman [85]. The precise mechanisms of the platelet antimicrobial
response and differential secretion remain to be elucidated.
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The ﬁnal steps of the haemostatic response to external injury, or
rupture of atherosclerotic plaque in the arterial circulation, lead to
restoration of the integrity of the vascularwall. This process involves or-
chestrated proliferation and migration of smooth muscle cells (SMCs),
ﬁbroblasts and endothelial cells. Platelets' wealth of growth factors
and chemokines is known to contribute to regulation of those processes.
Platelet derived growth factor (PDGF) in particular is instrumental in
regulating SMC proliferation and migration in both the arterial and
venous circulation [86]. Neointimal hyperplasia and restenosis, such as
often occurs following balloon angioplasty, were already shown to be
mediated by PDGF 25 years ago [87]. Subsequently approaches
targeting the PDGF signalling pathway developed but despite promise
in animal models, PDGF inhibition has not yet shown to be effective in
humans [88].
Another important mediator in healing and remodelling is platelet-
derived SDF-1αwhich mediates CD34+ bone marrow derived progen-
itor cell recruitment to the injury site and their differentiation into
endothelial progenitor cells [89–91]. Inhibition of SDF-1α binding to
its receptor CXCR4 was shown to retard diabetic wound healing in ex-
perimentalmodels by impairing cellularmigrationwhile concomitantly
prolonging the inﬂammatory response [92]. At the same time, platelet-
mediated differentiation of CD34+ progenitor cells into mature foam
cells is of particular importance in atherosclerotic plaque formation
[93]. SDF-1α is also a potent pro-angiogenic mediator, enhancing
CXCR4-expressing endothelial cell proliferation, differentiation,
sprouting and tube formation in vitro and in vivo [94–96]. Other pro-
and anti-angiogenic factors such as VEGF (vascular endothelial growth
factor) and endostatin are also released from platelets [97], supporting
their crucial role in regulating the revascularisation of the damaged
tissue.
In addition to angiogenic factors, platelets also store and secrete a
number of tumour necrosis factor (TNF)-α-related apoptosis regulators
such as CD95, Apo2-L and Apo3-L which can induce inﬂammatory
responses and apoptosis in other circulating cells, as well as anti-
apoptotic molecules [98]. The balance between pro-apoptotic and
anti-apoptotic molecules, adequately promoting survival or eliminating
the cells from the wound site, is also crucial for regulation of healing.
In summary, the increasing understanding of the role of platelet se-
cretion in wound healing and tissue regeneration led to the develop-
ment of multiple applications, especially in trauma management.
Autologous platelet-rich plasma gels and growth factor concentrates
are used in a number of clinical scenarios, from healing of acute skin
wounds and diabetic ulcers to regeneration of tendon, ligament and
nerve tissue [99]. Modulation of secretion for clinical beneﬁt on the
other hand is the area that remains to be further investigated.
6. Platelet secretion and disease
Platelets' wealth of potent bioactive molecules is essential for
the regulation of the complex physiological processes outlined so far.
However, their ability to inﬂuence other cells means that they are also
central to the pathophysiology of disease. Platelet secretion can cause
disease beyond the obvious thrombotic scenarios, such as atherosclero-
sis, or heart attacks and strokes resulting from occlusive thrombus
formation in circulation. Multiple roles in conditions from cancer
progression and metastasis, to chronic inﬂammatory conditions, sepsis
and acute lung injury have also been proposed.
6.1. Malignancy
Early evidence for platelet function in cancer progression was
originally derived from studies in a mouse model of severe thrombocy-
topenia [100]. In 1968, Gasic et al. reported that platelet depletion
caused by neuraminidase pre-treatment led to a signiﬁcant decreasein number of lung metastases following tumour inoculation [100]. It
was later found, that infusion of resting, but not degranulated platelets,
could rescue the tumour metastatic potential, in addition to preventing
thrombocytopenia-induced tumour bleeding [101]. Thus, platelet secre-
tion appears to be the essential permissive and protective factor for
tumour metastasis.
Platelet α-granules contain a number of growth factors that are im-
portant in physiological wound healing and angiogenesis including
VEGF, PDGF, epidermal growth factor (EGF), and transforming growth
factor beta (TGFβ) [102]. The same molecules can be ‘hijacked’ by can-
cer cells to potentiate tumour survival andmetastasis, which is essential
for tumour survival beyond 1–2 mm in size. PDGF as a potent mitogen
for mesenchymal cells including ﬁbroblasts, smooth muscle cells, and
glial cells, was a prime suspect in mediating cancer metastasis [103]. In-
deed, overexpression of the PDGF receptor on tumour cells correlates
with increased metastatic potential in breast cancer [104]. PDGF/PDGF-
receptor interaction was also found to promote lymphangiogenesis and
lymphatic extravasation in thyroid cancer [105]. Circulating VEGF, most-
ly derived from platelets, not only facilitates angiogenesis and increases
vascular permeability, which promotes tumour cell extravasation [106],
but was also recently implicated in the function of cancer stem cells
and tumour initiation [107]. Platelet-derived TGFβ, in synergy with
other platelet-bound factors, was recently shown to be an essential
permissive factor for metastasis, speciﬁcally in epithelial–mesenchy-
mal-like transition [108]. On the other hand, platelets also contain
anti-angiogenic factors (such as PF-4, TSP-1 and endostatin) that can
limit cancer survival and growth [109]. This again provides evidence
for themultifaceted and complex roles of platelet secretion in patholog-
ical processes. Regulating platelet secretion could be a viable target for
anti-metastatic therapies, and indeed, PF-4 is being developed as a
novel anti-angiogenic cancer therapy [110].
In addition, Schumacher et al. recently showed that Unc13dJinxmice,
that lack expression of Munc13-4, were protected from lungmetastases
and suggested that lack of ATP secretion from platelet dense granules
was responsible for that protection [111]. Although we and others [12,
14,112] had previously shown a defect in α-granule secretion in these
mice, consistent with an ampliﬁcatory role for secreted ADP
(as described earlier in this article andHarper et al. [112]), they convinc-
ingly argue that ATP acting via P2Y2 receptors on endothelial cells
contributes another mechanism that increases endothelial cell perme-
ability and facilitates tumour cell extravasation, additional to the well-
established pro-angiogenic functions of α-granule releasate.
6.2. Other conditions
Due to their ability to initiate and sustain inﬂammatory responses
platelets are often one of the main culprits and reasons for mortality
in a series of other conditions. Therefore in some cases, platelet inhibi-
tion or depletion correlates with better outcomes. The exception to
that is sepsis, where a role for platelets in exuberating the disease was
proposed. On the one hand, platelet accumulation in vital organs can
cause inﬂammatory responses by platelet-mediated immune cell re-
cruitment [113] and can lead to acute organ injury. On the other hand,
disseminated intravascular coagulation leads to thrombocytopenia
which in turn increases vascular permeability, normally stabilised by
platelet secreted VEGF [114]. This in turn can predispose to edema,
shock and organ failure that more often than not lead to death in severe
sepsis [115].
Theplatelet P-selectin/PSGL interactionmediating platelet–neutrophil
interaction in infection, is also a proposed mechanism for monocyte
recruitment accompanying transplanted graft rejection [116] and
blocking P-selectin was recently shown to protect mice from
antibody-mediated rejection [117]. Similarly, P-selectin mediated
neutrophil recruitment [118] and platelet-derived CXCL4–CCL5 hetero-
dimer formation [119] are thought to be major pathogenic contributors
to the acute lung injury.
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ﬂammatory bowel disease (elevated levels of RANTES are found in
Crohn's disease patients) [120], migraines (IL-1 and β-thromboglobulin
are implicated in their aetiology) [121] and asthma (increased P-
selectin mediated leukocyte recruitment thought to contribute to
pulmonary inﬂammation) [122]. Therefore it is reasonable to hypothesise
that many further conditions associated with systemic inﬂammation
could be linked to platelet function or dysfunction.
7. So… how is it all regulated?
As outlined in this review, the roles of platelets extend beyond initial
platelet adhesion and aggregation at the site of injury. Platelets are not
‘merely’ contributing to processes such as coagulation, inﬂammation,
and antimicrobial responses or wound healing, they are arguably cen-
tral and essential in themajority of those processes. As outlined, platelet
secretion of 300+ molecules from intracellular stores is likely to be a
major driver of those interactions (summarised in Fig. 4). Yet, clearly
our current understanding of platelet secretion at the molecular level
is insufﬁcient to explain how the careful balance between all the potent
mitogenic, pro-angiogenic, anti-angiogenic, pro-inﬂammatory, anti-
inﬂammatory and adhesive factors released from granules under
certain activation conditions is achieved. If all the contents of the
intracellular stores were released in an uncoordinated manner, the
thrombus growth and all the following events would be similarly unco-
ordinated. It seems implausible that just a handful of SNARE proteins
can achieve that. Therefore several other mechanisms and avenues
have been investigated recently.
One of the hypotheses put forward is that platelet granules are not
uniform, and that certain factors, especially α-granule cargoes, may be
differentially packaged and thus released ‘thematically’. Ma et al.
observed that platelet stimulation with speciﬁc protease-activated
receptor (PAR) 1 or PAR4 agonist resulted in the preferential release
of VEGF or endostatin, (anti- and pro-angiogenic factors, respectively)
[123]. Differential packaging of granules was a very attractive explana-
tion for that observation, and indeed, spinning-disk confocal micro-
scope images of resting platelets, clearly showing distinct localisation
of two of the main α-granule cargoes, ﬁbrinogen and vWF, have been
published [124]. Immunogold labelling by the Italiano group also
showed α-granule populations containing either endostatin or VEGF
but not both [125]. More recently however, a super-resolution analysis
of 15 platelet α-granule cargoes using 3D structured illuminationFig. 4. Summary of some of the platelet granule cargoes and their functional classiﬁcation.α-Gr
coagulation-related factors), hence amechanism(s) ensuring tight spatial and temporal regulati
of the physiological (green) and pathological (red) processes that are now known to be affecte
Many of those physiological and pathological processes can be affected by a combination of f
cargoes have multiple roles, while the roles of others still have not been fully elucidated.
Adapted from Golebiewska and Poole [59].microscopy (3D-SIM) failed to conﬁrm any functional co-localisation
[126]. van Nispen tot Pannerden et al. identiﬁed different classes of α-
granules, observing snapshots of resting platelets under EM [127].
They reported a distinct population of approximately 50 nm-wide
‘tubes’ that they designated ‘tubularα-granules’. They contained ﬁbrin-
ogen but not vWF, as opposed to the usual, ‘spherical’α-granuleswhich
contained both. Differential packaging of α-granule cargo remains an
attractive explanation for the observed separation of pro- and anti-
angiogenic releasates, but the difﬁculties associated with platelet re-
searchmean that we still lack deﬁnitive conﬁrmation of this hypothesis.
No similar studies on dense granule secretion exist.
In 2012, the Whiteheart group performed a systematic quantiﬁca-
tion of granule secretion using micro-ELISA arrays for 28 distinct
α-granule cargo molecules in response to 4 different agonists [10],
quantifying the kinetics of secretion of each cargo. This was the ﬁrst
time that kinetics of secretionweremeasured— no conclusive evidence
for the ‘fast’ dense granule, ‘slower’ α-granule and ‘slowest’ lysosome
secretion model previously existed. They found that not only secretion
of different cargoes varied depending on the agonist used, but that
there was also an overlap in secretion kinetics of cargoes of opposing
functions. In conclusion, they proposed that the kinetics of release
could not independently explain differential secretion and granule
shape, proximity to the membrane or cargo solubility is likely to inﬂu-
ence the kinetics [10]. It is also likely that different SNARE complexes
could drive the fusion with different kinetics— another reason to ques-
tion the ‘one sizeﬁts all’ SNARE complex in platelets that is currently ac-
cepted (SNAP23–VAMP8–STX11). SNARE redundancy and functional
specialisation have been described in other cells. For example two
endosomal SNARE complexes exist, with one mediating the early to
late endosome transport, while the other — late endosome to surface
step [128]. Similarly, human neutrophils have several different SNAREs
that regulate secretion of speciﬁc granules [129]. Therefore it is possible
that differential secretion of cargoes in platelets is also mediated by not
one, but several different SNARE complexes. In addition, it is thought
that platelet granules may fuse with each other or with the open cana-
licular system (OCS) rather than directly with the plasma membrane,
which could accounts for different secretion rates depending upon
the stimulation conditions [130]. Signalling cascades between agonist
stimulation and SNARE-mediated secretion events also remain largely
unknown. The accepted model of platelet signalling principally
converges on the increase in cytosolic calcium to drive the cellular ma-
chinery upon activation, but the signalling downstream of receptors isanules (left hand side) contain cargoes with often opposing actions (e.g. angiogenesis and
on of secretion is likely to be in place to allow platelets to exert theirmany functions. Some
d by platelet secretome are also listed (amber indicates both depending on the scenario).
actors. It should be noted that although functions are assigned to each cargo here, many
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events. Again, the nature of plateletsmeans that studying cell signalling
in real time is problematic. Finally, of course, dissecting platelet function
in vitro or in animal models of thrombosis does not necessarily reﬂect
their function in human health and disease, and this remains a major
challenge for future research. In summary, our understanding of plate-
let secretion is increasing, but remains rudimentary at the moment
with no clear answers to the question of how the remarkable complex-
ity is achieved.
8. Conclusions
Platelet secretion is undoubtedly of pivotal importance for regulat-
ing not only canonical platelet functions, but also mediating their
impact on other cells, and understanding platelet secretion may have
consequences reaching far beyond the ‘platelet ﬁeld’. Yet platelets re-
main lesswell studied in terms ofmechanisms governing their function,
relative to other secretory cells such asneuroendocrine or immune cells.
In this review we have shown examples of the ways in which platelet
secretion is essential for sustaining haemostasis and ensuring an
adequate response to injury, but also how the same mechanisms
may mediate pathological responses. This means that any approaches
targeting platelets or platelet secretion have to be carefully tailored for
each speciﬁc application. Dissectingmechanisms of differential secretion
of different cargoes may be helpful in designing therapies that can avoid
currently common bleeding side effects while limiting pathological
inﬂammation, tissue hypertrophy or cancer cell metastasis.
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